HOME >> MEDICINE >> NEWS
Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer

CD40L Moved Forward Based On Outcomes Of Multi-Dose Safety Trial

SEATTLE - Immunex Corporation (Nasdaq: IMNX) announced today that it has launched a Phase II trial of the investigational agent CD40 Ligand (CD40L) in the most common form of kidney cancer, renal cell carcinoma. The company is continuing the development of CD40L based on results of a multi-dose Phase I trial of the drug in advanced cancer patients.

The Phase I study, which evaluated escalating doses of CD40L in patients with recurrent solid tumors and lymphoma, has been completed and the objectives of the study were met. The results of this multi-dose study will be presented at a future medical meeting. Several pre-clinical studies on the anti-tumor effect of CD40L will be presented next week at the 35th Annual Meeting of the American Society of Clinical Oncology (ASCO). In these studies, conducted in both mice and fresh human tumor samples, CD40L inhibited tumor growth in multiple solid tumor types, such as breast, lung, ovarian and colon.

"Based on the results of these safety trials, Immunex is moving forward with a Phase II trial of CD40L in metastatic renal cell carcinoma," said Ann Hayes, M.D., senior vice president, medical development, Immunex. "Patients with this disease currently have limited treatment options. Treatment with CD40L represents a novel approach to treating cancer, by potentially having a direct effect on tumor cells and by stimulating the immune system to recognize and seek out cancer cells for destruction."

The study, being conducted in three cancer treatment centers across the United States, will evaluate the safety and efficacy of the drug in metastatic renal cell carcinoma.

Approximately 30,000 new cases of kidney cancer will be diagnosed this year in the United States and about 11,900 people will die from this disease. It is the 8th most common cancer in men and the 10th most common in women. Ren
'"/>

Contact: Lisa Crisera
criseral@immunex.com
206-389-4346
Immunex Corporation
14-May-1999


Page: 1 2

Related medicine news :

1. Immunex Files Supplemental NDA for NOVANTRONE
2. Immunexs TRAIL Molecule Shows Potential As Anti-Tumor Agent
3. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
4. Advances in plasma physics at Annual APS Meeting
5. Advances in plasma physics at Annual APS Meeting
6. Advances in understanding brain circuits responsible for tics in Tourettes shed light on disorder
7. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
8. Advances emerging in hepatitis management
9. Advances in prevention and treatment research hold promise for pipeline
10. Advances in MRI imaging may lead to new standards for faster diagnosis of multiple sclerosis
11. Peanut Allergy: Major Advances in Treatment and Education

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2018)... ... , ... The National Cancer Institute estimates that 1.7 million new cases of ... for cancer and we typically associate the disease with old age, about 9 percent ... treatment and advanced therapies, increasing numbers of these patients survive their disease and face ...
(Date:11/15/2018)... ... November 15, 2018 , ... Lisa Vuich MD ... for Specialty MED Training will take the stage during the 26th World ... 2019. Dr. Vuich is leading a CME workshop hosted by Tailor Made Compounding ...
(Date:11/14/2018)... ... November 14, 2018 , ... Entrepreneur ... All-In-One Video Ecommerce Solution, to power its "Ask an Expert" online mentor marketplace. ... live 30 and 60-minute one-to-one virtual sessions that are focused on starting and ...
(Date:11/14/2018)... ... 14, 2018 , ... The Austin-area sports medicine team at Medicine ... pull out the healthcare plan paperwork to review coverage and assess how many unused ... most people can benefit by taking a few minutes for an insurance plan evaluation. ...
(Date:11/13/2018)... ... November 13, 2018 , ... Azzur Labs, ... the opening of its newest laboratory located in Cary, NC. Seated in the ... services to top U.S. manufacturers and brings additional jobs to the Raleigh area. ...
Breaking Medicine News(10 mins):
(Date:11/15/2018)... Del. (PRWEB) , ... November 15, 2018 , ... ... over 61% in 2016 and is estimated to continue its dominance during the ... industrial segment. Mobile exoskeleton provides mobility to the wearer while augmenting strength to ...
(Date:11/15/2018)... Calif. (PRWEB) , ... November 15, 2018 , ... ... instruments, today announced its participation in the California Optometric Association’s Monterey Fall Symposium. ... The show provides a platform for connecting with hundreds of doctors of optometry. ...
(Date:11/14/2018)... ... November 14, 2018 , ... Planet DDS (PDDS), ... Hannah Cohen was joining the company as its new Vice President of Operations. ... DaVita, one of the nation’s leading managed care providers. At DaVita, Hannah oversaw ...
Breaking Medicine Technology:
Cached News: